Because of its expression in breast cancer, GATA3-AS1 has also been proposed as a potential biomarker of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer of Luminal B subtype [17]; it is also related to the immune response since it regulates the differentiation of Th2 lymphocytes, as mentioned before [16]. Here, GATA3 is linked to breast carcinoma.